图表| 根据讲者 PPT 制作 题图| KDIGO 官网 参考文献(上下滑动查看) [1] Wong MMY, Tu C, Li Y, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes...
题图| KDIGO 官网 参考文献(上下滑动查看) [1] Wong MMY, Tu C, Li Y, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2019;13(4):613-...
图表| 根据讲者 PPT 制作 题图| KDIGO 官网 参考文献(上下滑动查看) [1] Wong MMY, Tu C, Li Y, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidn...
对于CKD 患者,2024 版《改善全球肾脏病预后组织(KDIGO)CKD 评估与管理临床实践指南》(简称 2024 KDIGO CKD 指南)推荐钠-葡萄糖协同转运蛋白 2 抑制剂(SGLT2i)作为一线治疗药物[1],《中国慢性肾脏病早期评价与管理指南》也推荐 SGLT2...
对于CKD 患者,2024 版《改善全球肾脏病预后组织(KDIGO)CKD 评估与管理临床实践指南》(简称 2024 KDIGO CKD 指南)推荐钠-葡萄糖协同转运蛋白 2 抑制剂(SGLT2i)作为一线治疗药物[1],《中国慢性肾脏病早期评价与管理指南》也推荐 SGLT2i 作为优选治疗药物[2]。
Strategies to improve outcomes will require a global effort directed at the earlier stages of CKD. The rationale for a global initiative to address this problem is simple and self-evident. The epidemic of CKD is global. The adverse outcomes of CKD are universal, as are the underlying science ...
"Dapagliflozin was found to be safe in patients with CKD stages 4-5," Hung noted. "Recognizing the Evidence Gap" Study discussant David C. Wheeler, MD, a professor of kidney medicine at University College London, noted that currentKDIGO guidelineson the management of CKD recommend the use of...
KDIGO advises that GFR and albuminuria levels be used together, rather than separately, to improve prognostic accuracy in the assessment of CKD. [5] More specifically, the guidelines recommended the inclusion of estimated GFR and albuminuria levels when evaluating risks for overall mortality, cardiovasc...
KDIGO将全因死亡作为CKD最重要的预后之一培哚普利改善CKD患者的预后证据充分培哚普利改善CKD患者预后的机制探讨 全球成人CKD患病率10-13％!4－6亿人患有CKD!国际肾脏病学会、国际肾脏病联合会于2006年确定每年3月份第二个星期四为“世界肾脏病日”我国CKD患病率为10.8%，据此估计中国成人中有1.20亿为慢性肾脏病...
改善全球肾病预后组织(KDIGO)曾发表了有关慢性肾脏病 - 矿物质与骨代谢异常(CKD-MBD)的诊断、评估、预防与治疗指南。但是,当时缺乏新的高质量证据,该指南较少讨论如何在慢性肾脏病 CKD3～4 期患者中处理继发性甲状旁腺功能亢进(SHPT)。 2014 ...